Martin Dow Gets DRAP License for Clinical Reagents Facility in Pakistan

Martin Dow Gets DRAP License for Clinical Reagents Facility in Pakistan

Martin Dow has received an official license from the Drug Regulatory Authority of Pakistan (DRAP) to start re-filling and labelling clinical chemistry reagents at its new down-filling facility. This is a big step toward import substitution in Pakistan’s healthcare and diagnostics sector.

---

🏭 Facility Details

The new project was built with an investment of around Rs. 50 million.

Total area: 2,600 square feet

Production capacity: 6 million packs per year

It is the first facility of its kind in Pakistan, designed to meet the country’s current and future diagnostic needs.

The plant follows international standards of efficiency, safety, and hygiene, ensuring high-quality production.

---

💬 Statement from Martin Dow

Dr. Suleman Alvi, Country Head of Martin Dow Specialities Pvt Ltd, said:

> “The DRAP approval is a landmark achievement. It will help Pakistan reduce reliance on imported diagnostic reagents and make healthcare solutions more affordable. At Martin Dow, we are committed to innovation, local production, and better healthcare outcomes.”

---

🔬 Importance for Pakistan’s Healthcare

This milestone will:

Reduce dependency on imported reagents

Improve accessibility for labs across the country

Support local production and innovation in diagnostics

The reagents are ready-to-use liquid solutions for testing in clinical chemistry analyzers, widely used in pathology labs.

---

📌 Key Takeaway

With this facility, Martin Dow is not only supporting self-reliance in healthcare but also playing a role in making diagnostic tests cheaper and more accessible for Pakistanis.